LY6K and malignant glioma: ASPH has been reported as a potential therapeutic target for malignant glioma (PMID: 27981247) (32, 33), and LY6K is a novel bladder cancer molecular target that integrated genome-wide analysis (PMID: 21063397) (34, 35).